Selective. Targeted. Innate.

NanoGhost is a pre-clinical biotechnology company developing a novel, versatile and highly selective targeted drug delivery platform naturally targeted to inflamed tissues including tumors. The company generates mesenchymal stem-cell derived nano-vesicles that may be loaded with a variety of therapeutics for safe and targeted delivery to the organ of choice. NanoGhost’s technology allows for the first time generation of an “off the shelf”, consistent, precise and cost-effective targeted drug delivery system with a potential to revolutionize current oncological landscape.

Investing partner / fund: